Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
AIMS: Exercise capacity is reduced in heart failure (HF) patients, due mostly to skeletal muscle abnormalities including impaired energy metabolism, mitochondrial dysfunction, fibre type transition, and atrophy. Glucagon-like peptide-1 (GLP-1) has been shown to improve exercise capacity in HF patients. We investigated the effects of the administration of a dipeptidyl peptidase (DPP)-4 inhibitor on the exercise capacity and skeletal muscle abnormalities in an HF mouse model after myocardial infarction (MI). METHODS AND RESULTS: MI was created in male C57BL/6J mice by ligating the left coronary artery, and a sham operation was performed in other mice. The mice were then divided into two groups according to the treatment with or without a DPP-4 inhibitor, MK-0626 [1 mg/kg body weight (BW)/day] provided in the diet. Four weeks later, the exercise capacity evaluated by treadmill test was revealed to be limited in the MI mice, and it was ameliorated in the MI + MK-0626 group without affecting the infarct size or cardiac function. The citrate synthase activity, mitochondrial oxidative phosphorylation capacity, supercomplex formation, and their quantity were reduced in the skeletal muscle from the MI mice, and these decreases were normalized in the MI + MK-0626 group, in association with the improvement of mitochondrial biogenesis. Immunohistochemical staining also revealed that a shift toward the fast-twitch fibre type in the MI mice was also reversed by MK-0626. Favourable effects of MK-0626 were significantly inhibited by treatment of GLP-1 antagonist, Exendin-(9-39) (150 pmol/kg BW/min, subcutaneous osmotic pumps) in MI + MK-0626 mice. Similarly, exercise capacity and mitochondrial function were significantly improved by treatment of GLP-1 agonist, Exendin-4 (1 nmol/kg/BW/h, subcutaneous osmotic pumps). CONCLUSIONS: A DPP-4 inhibitor may be a novel therapeutic agent against the exercise intolerance seen in HF patients by improving the mitochondrial biogenesis in their skeletal muscle.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The notable advantage for muscle preservation seems to be the use of glucagon-like peptide-1 (GLP-1) receptor agonists34,35 and dipeptidyl peptidase-4 inhibitors (DPP-4i),36–38 which not only minimally affects muscle mass loss but also stimulates muscle contraction and aid in muscle recovery.”
From Imaging of Sarcopenia in Type 2 Diabetes Mellitus (2024) · cites this paper as [38]
Citations
Cites
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · cited 9×
“The work was significantly increased in MIþMK-0626þVe mice compared to the MIþNDþVe mice, and this was completely inhibited in the MIþMK-0626þ Ex-(9-39) (GLP-1 receptor antagonist) mice (respectively, P< 0.”
BackgroundMethodInfluentialAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 9×
“The work was significantly increased in MIþMK-0626þVe mice compared to the MIþNDþVe mice, and this was completely inhibited in the MIþMK-0626þ Ex-(9-39) (GLP-1 receptor antagonist) mice (respectively, P< 0.”
BackgroundMethodInfluentialThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Mancini, D. M., Eisen, H., Kussmaul, W., Mull, R., Edmunds, L. H., & Wilson, J. R. (1991) · Circulation · doi:10.1161/01.cir.83.3.778 · Cited by 1,882
Belardinelli, R., Georgiou, D., Cianci, G., & Purcaro, A. (1999) · Circulation · doi:10.1161/01.cir.99.9.1173 · Cited by 1,099
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Exercise limitation in chronic heart failure: Central role of the periphery
Clark, A. L., Poole-Wilson, P. A., & Coats, A. J. S. (1996) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00323-3 · Cited by 524
Cited by
Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
Hong, Y., Lee, J. H., Jeong, K. W., Choi, C. S., & Jun, H. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12434 · Cited by 188
“In support of our results, recent studies reported that the inhibitors of DPP4, a GLP-1 degradation enzyme, are associated with improvement of reduced muscle mass in diabetic and elderly diabetic patients(15,71) and with improvement of mitochondrial biogenesis in a heart failure mouse model.(16)”
ResultSayed, N. H., Fathy, N., Kortam, M. A., Rabie, M. A., Mohamed, A. F., & Kamel, A. S. E. D. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00805-5 · Cited by 146
Massimino, E., Izzo, A., Riccardi, G., & Della Pepa, G. (2021) · Cells · doi:10.3390/cells10081958 · Cited by 102
Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
Lisco, G., Disoteo, O. E., De Tullio, A., De Geronimo, V., Giagulli, V. A., Monzani, F., Jirillo, E., Cozzi, R., Guastamacchia, E., De Pergola, G., et al. (2023) · Nutrients · doi:10.3390/nu16010063 · Cited by 101
GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway
Wu, L., Zhou, M., Li, T., Dong, N., Yi, L., Zhang, Q., & Mi, M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119300 · Cited by 101
Metadata
- Authors
- Takada, S., Masaki, Y., Kinugawa, S., Matsumoto, J., Furihata, T., Mizushima, W., Kadoguchi, T., Fukushima, A., Homma, T., Takahashi, M., Harashima, S., Matsushima, S., Yokota, T., Tanaka, S., Okita, K., & Tsutsui, H.
- Affiliations
- Hokkaido University (JP)
- Hokusho University (JP)
- Corresponding author
- Kinugawa, Shintaro
- ORCID
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-07-21
- Volume
- 111
- Issue
- 4
- Pages
- 338-347
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W2510316798
- Cited by
- 78
- References
- 40
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 7 · 2022: 6 · 2021: 10 · 2020: 11 · 2019: 11 · 2018: 11 · 2017: 8
- FWCI
- 20.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cardiovascular Research (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Japan Foundation for Applied Enzymology
- Ministry of Education, Culture, Sports, Science and Technology (26750331, 26350879)
- Hokkaido University
- Japan Society for the Promotion of Science (16K16607, 15K01625, 26750331)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Cardiovascular and exercise physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- DPP-4 inhibitors, heart failure, exercise capacity, exercise intolerance, GLP-1 receptor, mitochondrial biogenesis, skeletal muscle, myocardial infarction, mitochondrial dysfunction, exendin-4, exendin-9-39, citrate synthase, oxidative phosphorylation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Organelle Biogenesis, Disease Models, Animal, Male, Mice, Inbred C57BL, Mitochondria, Myocardial Infarction, Peptides, Triazoles, Venoms, Muscle, Skeletal, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling. https://app.cochat.ai/papers/10.1093/cvr/cvw182
- The paper
- Takada, S., Masaki, Y., Kinugawa, S., Matsumoto, J., Furihata, T., Mizushima, W., Kadoguchi, T., Fukushima, A., Homma, T., Takahashi, M., Harashima, S., Matsushima, S., Yokota, T., Tanaka, S., Okita, K., & Tsutsui, H. (2016). Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling. Cardiovascular Research. https://doi.org/10.1093/cvr/cvw182
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.